NCT02118051View on ClinicalTrials.gov

Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Infertility
Interventions
DRUG

Ganirelix 0.25 mg.

Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.

DRUG

Recombinant choriogonadotropin alfa

Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed

DRUG

Micronized natural progesterone.

Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.

Trial Locations (1)

46026

Human Reproduction Unit of the La Fe University and Politechnic Hospital, Valencia

All Listed Sponsors
lead

Instituto de Investigacion Sanitaria La Fe

OTHER

NCT02118051 - Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response. | Biotech Hunter | Biotech Hunter